Aprea Therapeutics, Inc. financial data

Symbol
APRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
3805 Old Easton Road, Doylestown, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 793 % +5.83%
Debt-to-equity 15.1 % -45.9%
Return On Equity -57.9 % -4.33%
Return On Assets -47.9 % -5.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.43M shares +45.4%
Common Stock, Shares, Outstanding 5.43M shares +45.4%
Entity Public Float 10M USD -28.6%
Common Stock, Value, Issued 5.44K USD +45.5%
Weighted Average Number of Shares Outstanding, Basic 5.94M shares +59%
Weighted Average Number of Shares Outstanding, Diluted 5.94M shares +59%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.2M USD -40.3%
General and Administrative Expense 7.03M USD +39.1%
Operating Income (Loss) -14.8M USD -16.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -13.5M USD -1.67%
Earnings Per Share, Basic -2.77 USD/shares -111%
Earnings Per Share, Diluted -2.77 USD/shares -111%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.2M USD +3.53%
Assets, Current 26.5M USD +3.29%
Property, Plant and Equipment, Net 87K USD +0.87%
Operating Lease, Right-of-Use Asset 107K USD -57.2%
Other Assets, Noncurrent 282K USD
Assets 26.9M USD +4.38%
Accounts Payable, Current 1.15M USD +33.8%
Employee-related Liabilities, Current 673K USD -35.3%
Liabilities, Current 3.64M USD -12.7%
Operating Lease, Liability, Noncurrent 28.1K USD -16.9%
Liabilities 3.95M USD -48.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10.6M USD +0.29%
Retained Earnings (Accumulated Deficit) -318M USD -4.43%
Stockholders' Equity Attributable to Parent 21.9M USD +8.17%
Liabilities and Equity 26.9M USD +4.38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.94M USD -32.1%
Net Cash Provided by (Used in) Financing Activities 14.7M USD +186%
Net Cash Provided by (Used in) Investing Activities -7.98K USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 5.43M shares +45.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.3M USD +3.53%
Deferred Tax Assets, Valuation Allowance 49.4M USD +13.3%
Deferred Tax Assets, Gross 49.4M USD +13.3%
Operating Lease, Liability 111K USD -56.4%
Payments to Acquire Property, Plant, and Equipment 7.98K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.5M USD +1.5%
Lessee, Operating Lease, Liability, to be Paid 112K USD -57.2%
Property, Plant and Equipment, Gross 138K USD +205%
Operating Lease, Liability, Current 111K USD -50.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 53.2K USD -72.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.42K USD -82.1%
Deferred Tax Assets, Operating Loss Carryforwards 41.8M USD +7.58%
Preferred Stock, Shares Authorized 40M shares 0%
Operating Lease, Payments 246K USD -3.72%
Additional Paid in Capital 351M USD +4.51%
Depreciation, Depletion and Amortization 6.16K USD +1402%
Share-based Payment Arrangement, Expense 149K USD +96.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%